EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PROTAC Enabling Formulation In Vivo : Implications of the Polymeric Carrier Eudragit E PO

Nicole Hofmann iD, Florian Johann, Katharina Krollik, Andreas Marx, Heide Marika Duevel iD, Marc Lecomte, Meike Harms, Karsten Mäder iD

Molecular Pharmaceutics · 06.10.2025 · 22 (10) · 5845-5859

DOI: 10.1021/acs.molpharmaceut.5c00303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 24.08.2025. Verfasst von Nicole Hofmann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Global Drug Product Development, Orals Development, the Healthcare Business of Merck KGaA, Frankfurter Straße 250, Darmstadt 64293, Germany. Hauptthemen laut MEDLINE: Polymers, Drug Carriers. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium f?r Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis targeting chimeras (PROTACs) are heterobifunctional degraders with a unique mode of action that permits access to "undruggable" targets. These molecules pose challenges in terms of solubility and bioavailability due to their physicochemical properties. So far, very little information is available on the potential of enabling formulations of PROTACs in pharmacokinetic studies. In a previous work of our group, amorphous spray-dried formulations (SDDs) of the model PROTAC MS4078 were developed. However, the potential of the amorphous solid dispersions of the PROTAC MS4078 has not yet been examined in vivo. The present study reports on the evaluation of an SDD containing MS4078 and E PO in comparison to a solution vehicle in a pharmacokinetic study in mice. Unexpectedly, very little exposure was found for both formulations. For a deeper investigation of their supersaturation and precipitation performance, the two formulations were tested in a two-stage precipitation assay with media that mimic physiological conditions in mice, which includes various bile salt and phospholipid concentrations. In this assay, the solution vehicle turned out to be a potent solubility enhancer. For the SDD, however, very different and complex dissolution profiles were obtained. The concentration at each time point was dependent on the bile salt and phospholipid concentration. Further in vitro tests revealed that E PO, the bile salt, and phospholipid interacted and induced a phase separation. This affected the solubilization and stabilization of the model PROTAC and may explain the differences regarding its in vitro performance. These findings are important to consider when designing future studies including E PO as polymeric carrier and species with high bile salt and phospholipid concentrations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PolymersDrug CarriersAnimalsMiceSolubilityBiological AvailabilityMaleChemistry, PharmaceuticalDrug Compounding

Stichwörter der Autor:innen

Eudragitamorphous solid dispersionsbile saltsbioavailabilityenabling formulationproteolysis targeting chimeras

Substanzen

PolymersDrug Carriers

Autor:innen und Institutionen

  • Global Drug Product Development, Orals Development, the Healthcare Business of Merck KGaA, Frankfurter Straße 250, Darmstadt 64293, Germany.
  • Institute of Pharmacy, Faculty I of Natural Sciences, Martin Luther University Halle-Wittenberg, Kurt-Mothes-Strasse 3, Halle (Saale) 06120, Germany.
  • Site Management Lab Services, Merck KGaA, Frankfurter Straße 250, Darmstadt 64293, Germany.
  • Global Research and Development, NCE DMPK, the Healthcare Business of Merck KGaA, Frankfurter Straße 250, Darmstadt 64293, Germany.

ORCID-Profile: Nicole Hofmann, Heide Marika Duevel, Karsten Mäder

Förderung

  • Bundesministerium f?r Bildung und Forschung

Zitieren

APA

Hofmann, N., Johann, F., Krollik, K., Marx, A., Duevel, H. M., Lecomte, M., Harms, M., & Mäder, K. (2025). PROTAC Enabling Formulation In Vivo : Implications of the Polymeric Carrier Eudragit E PO. Molecular Pharmaceutics, 22(10), 5845-5859. https://doi.org/10.1021/acs.molpharmaceut.5c00303

Vancouver

Hofmann N, Johann F, Krollik K, Marx A, Duevel HM, Lecomte M, et al. PROTAC Enabling Formulation In Vivo : Implications of the Polymeric Carrier Eudragit E PO. Molecular Pharmaceutics. 2025;22(10):5845-5859. doi:10.1021/acs.molpharmaceut.5c00303

BibTeX
@article{Hofmann2025,
  author = {Hofmann, Nicole and Johann, Florian and Krollik, Katharina and Marx, Andreas and Duevel, Heide Marika and Lecomte, Marc and Harms, Meike and Mäder, Karsten},
  title = {PROTAC Enabling Formulation In Vivo : Implications of the Polymeric Carrier Eudragit E PO},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {10},
  pages = {5845--5859},
  doi = {10.1021/acs.molpharmaceut.5c00303}
}
Kostenlos starten →